Processa Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows (Parenthetical) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Purchase Agreement [Member] \| Lincoln Park Capital Fund LLC [Member]
Shares issued in connection with the Purchase Agreement with Lincoln Park	123,609
Common Stock [Member]
Shares issued in satisfaction of accrued director fees	17,572
Shares issued in connection with the Purchase Agreement with Lincoln Park	123,609
Shares issued in connection with license agreement	100,000	144,689
Common Stock [Member] \| Licensing Agreement [Member]
Shares issued in connection with license agreement	100,000	100,000